StreetInsider
Log in to your account:
Log in
Signup
Home
EPS Insider
Event Calendar
Conferences
Classic Site
Upgrade to SI Premium - Free Trial
FDA posts briefing documents on Merck (MRK) /Ridgeback antiviral molnupiravir
November 26, 2021 9:07 AM
FDA posts briefing ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
Categories
FDA
Hot FDA News
Next Articles
2 Reasons Why Citi Downgraded Merck (MRK) to Neutral Today, Opened a Negative Catalyst Watch
November 29, 2021 6:45 AM
Merck (MRK) and Eisai Announces EU Approval of LENVIMA Plus KEYTRUDA as First-Line Treatment for Adult Patients With Advanced Renal Cell Carcinoma
November 29, 2021 5:52 AM
Merck (MRK), Ridgeback Biotherapeutics Provide Update on Results from MOVe-OUT Study of Molnupiravir, an Investigational Oral Antiviral Medicine, in At Risk Adults With Mild-to-Moderate COVID-19
November 26, 2021 6:46 AM
Merck and Ridgeback Biotherapeutics Provide Update on Results from MOVe-OUT Study of Molnupiravir, an Investigational Oral Antiviral Medicine, in At Risk Adults With Mild-to-Moderate COVID-19
November 26, 2021 6:45 AM
